Tekmira Pharmaceuticals has obtained a worldwide, non-exclusive license to a novel RNAi payload technology, Unlocked Nucleobase Analog (UNA), from Marina Biotech. The UNA technology will be used for the development of RNAi therapeutics to treat disease by silencing specific disease causing genes. Marina will receive an upfront payment plus milestone and royalty payments on products developed by Tekmira that use UNA technology. Financial terms were not disclosed.
"Our license to Marina's UNA technology expands and diversifies our foundation of technologies that enable us to develop RNAi therapeutics. With Tekmira's leading LNP delivery technology, a strong balance sheet, and access to multiple RNAi payload technologies, we are well positioned to aggressively advance multiple products into human clinical trials," said Dr. Mark J. Murray, Tekmira's president and chief executive officer.
Tekmira Licenses Marina Biotech’s RNAi Technology
Published November 29, 2012
blog comments powered by Disqus